Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 7287 pages

Showing 201 - 250


hematologic malignancies
immunotherapy

EBV-Positive Posttransplantation Lymphoproliferative Disease: T-Cell Immunotherapy Efficacy

In the phase III ALLELE trial reported in The Lancet Oncology, Mahadeo et al found that the Epstein-Barr virus (EBV)-specific T-cell immunotherapy tabelecleucel produced high response rates—and few of the toxicities associated with other adoptive T-cell therapies—in allogeneic hematopoietic stem...

myelodysplastic syndromes

MRD Markers and Outcomes in Patients With MDS After Stem Cell Transplant

In a Scandinavian study reported in the Journal of Clinical Oncology, Tobiasson et al found that individual-patient measurable residual disease (MRD) could be assessed by next-generation sequencing (NGS) and droplet digital polymerase chain reaction (ddPCR) to predict outcomes in patients with...

breast cancer
supportive care

Skin Microbiome and Severe Radiodermatitis in Patients With Breast Cancer

In a German single-institution study reported in JAMA Oncology, Hülpüsch et al identified skin microbiome characteristics associated with severe radiodermatitis in women receiving adjuvant radiotherapy for breast cancer. Study Details The study included 20 consecutively enrolled women who received...

prostate cancer

Localized Prostate Cancer: Functional Outcomes After Specific Treatments

In an observational cohort study reported in JAMA, Al Awamlh et al identified adverse functional outcomes after localized prostate cancer treatment among patients with favorable- and unfavorable-prognosis disease.  Study Details The study included 2,445 patients from five SEER (Surveillance,...

prostate cancer

Metastatic Castration-Resistant Prostate Cancer: LuPSMA vs Cabazitaxel

As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, the Australian phase II TheraP trial has shown similar overall survival with lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) vs cabazitaxel in patients with prostate-specific membrane...

leukemia

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

In a single-center phase I/II study reported in the Journal of Clinical Oncology, Nicholas J. Short, MD, and colleagues found that treatment with azacitidine, venetoclax, and gilteritinib produced a high response rate in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML);...

skin cancer

Triplet Without or With Ipilimumab in Kidney Transplant Recipients With Advanced Cutaneous Cancers

In a small phase I/II trial reported in the Journal of Clinical Oncology, Schenk et al found that treatment with tacrolimus, prednisone, and nivolumab without or with ipilimumab produced few responses in kidney transplant recipients with advanced skin cancers, with treatment-related allograft loss...

prostate cancer

Intensification of ADT in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer After Radical Prostatectomy

As reported in the Journal of Clinical Oncology by Aggarwal et al, interim analysis of the phase III PRESTO trial showed that the addition of apalutamide as well as the addition of apalutamide plus abiraterone acetate/prednisone (AAP) to androgen-deprivation therapy (ADT) improved prostate-specific ...

lymphoma

Golidocitinib in Relapsed or Refractory Peripheral T-Cell Lymphoma

In a phase II trial (JACKPOT8 Part B) reported in The Lancet Oncology, Song et al found that the selective JAK1 tyrosine kinase inhibitor golidocitinib showed activity in patients with relapsed or refractory peripheral T-cell lymphoma. Study Details In the trial, 104 patients from sites in...

head and neck cancer

HPV-Related Oropharyngeal Carcinoma: Tumor Hypoxia–Directed Treatment

In a single-institution phase II trial reported in the Journal of Clinical Oncology, Nancy Y. Lee, MD, and colleagues found that tumor hypoxia is a promising marker for radiotherapy dose among patients receiving chemoradiotherapy for human papillomavirus (HPV)-related oropharyngeal carcinoma. As...

prostate cancer

Actinium-225–PSMA Radioligand Therapy for Prostate Cancer

In a retrospective study (WARMTH Act) reported in The Lancet Oncology, Sathekge et al found that actinium-225–prostate-specific membrane antigen (PSMA) radioligand therapy showed activity in patients with metastatic castration-resistant prostate cancer.   Study Details The study consisted of 448...

survivorship
cardio-oncology

Survivors of Childhood Cancer With High Anthracycline Exposure: Can a Beta-Blocker Improve Cardiac Function?

In a U.S./Canadian phase IIb trial (PREVENT-HF) reported in The Lancet Oncology, Armenian et al found that the beta-blocker carvedilol did not significantly improve cardiac function—measured as standardized left ventricular wall thickness–dimension ratio Z score (LVWT/Dz)—vs placebo in survivors of ...

issues in oncology
cost of care

Effects of Switch to High-Deductible Health Plans for Patients With Cancer

In a study reported in JAMA Oncology, Trad et al found that individuals with cancer in the United States who were switched from low- to high-deductible employer-sponsored health plans had higher out-of-pocket costs but no reduction in the number of oncologist visits; these patients, however, had...

lung cancer

Addition of Nivolumab to Chemotherapy in EGFR-Mutant Metastatic NSCLC After Disease Progression on Prior Therapy

As reported in the Journal of Clinical Oncology by Tony Mok, MD, FRCPC, FASCO, and colleagues, final results of the primarily Asian phase III CheckMate 722 trial showed no progression-free survival benefit with the addition of nivolumab to chemotherapy in patients with EGFR-mutant metastatic...

breast cancer

Addition of Palbociclib to Letrozole in ER-Positive, HER2-Negative Advanced Breast Cancer: Overall Survival in PALOMA-2

As reported in the Journal of Clinical Oncology by Dennis J. Slamon, MD, PhD, and colleagues, the phase III PALOMA-2 trial showed no overall survival benefit with the addition of palbociclib to letrozole in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer with no...

skin cancer

mTOR Inhibitor, Prednisone, and Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

In a small single-center phase I trial reported in the Journal of Clinical Oncology, Glenn J. Hanna, MD, and colleagues found that immunosuppressant treatment with an mTOR inhibitor and prednisone plus immunotherapy with cemiplimab-rwlc resulted in durable responses and no allograft loss in adult...

skin cancer

Adjuvant Treatment of Resected Melanoma: mRNA-Based Personalized Therapy Plus Immunotherapy

In the phase IIb KEYNOTE-942 trial reported in The Lancet, Jeffrey S. Weber, MD, PhD, and colleagues found that the addition of adjuvant mRNA-4157—a novel mRNA-based individualized neoantigen therapy—to pembrolizumab numerically improved recurrence-free survival in patients with completely resected ...

bladder cancer

Sacituzumab Govitecan Plus Pembrolizumab in Metastatic Urothelial Cancer Progressing After Platinum-Based Chemotherapy

In a cohort of the phase II TROPHY-U-01 trial (cohort 3) reported in the Journal of Clinical Oncology, Petros Grivas, MD, PhD, and colleagues found that the combination of sacituzumab govitecan-hziy and pembrolizumab showed activity in patients with metastatic urothelial cancer and disease...

lung cancer

Accelerated Hypofractionated Chemoradiation With Adaptive SABR Boost in Locally Advanced, Unresectable NSCLC

In a U.S. single-center radiation dose-expansion study reported in JAMA Oncology, Wu et al found that chemoradiation with adaptively increased stereotactic ablative radiotherapy (SABR) boost doses was safe and effective in patients with locally advanced, unresectable non–small cell lung cancer...

sarcoma
immunotherapy
cardio-oncology

Immunotherapy Outcomes in Patients With Primary Cardiac Soft-Tissue Sarcomas

In a U.S. multicenter retrospective analysis reported in JACC: CardioOncology, Amin H. Nassar, MD, and colleagues found that immune checkpoint inhibition resulted in mostly moderate activity in patients with primary cardiac soft-tissue sarcomas. Study Details The study included 24 patients with...

leukemia

Intensified vs Standard Induction in Younger Patients With Newly Diagnosed AML

In a UK trial (NCRI AML19) reported in the Journal of Clinical Oncology, Russell et al found that intensified induction therapy with FLAG-Ida (fludarabine, cytarabine, granulocyte colony–stimulating factor, and idarubicin) plus gemtuzumab ozogamicin did not improve overall survival in younger...

lung cancer

Rate of Second Primary Lung Cancers With Lobar vs Sublobar Resection of T1aN0 NSCLC

As reported in the Journal of Clinical Oncology by Thomas E. Stinchcombe, MD, and colleagues, an analysis from the phase III Cancer and Leukemia Group B 140503/Alliance trial has shown high rates of second primary lung cancers with both sublobar and lobar resections for T1aN0 non–small cell lung...

gynecologic cancers

OVHIPEC-1 Trial: Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Improves Survival in Advanced Ovarian Cancer

The final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall survival benefits at 10 years in women with advanced ...

cardio-oncology

Use of Direct Oral Anticoagulant Agents in Active Cancer: Meta-Analysis

In a systematic review and meta-analysis reported in JACC: CardioOncology, Fujisaki et al found no significant differences among direct oral anticoagulant agents (DOACs) in the prevention of recurrent venous thromboembolism (VTE) associated with active cancer, whereas significant differences in...

pancreatic cancer

Gemcitabine/Paclitaxel vs Gemcitabine Alone After FOLFIRINOX in Metastatic Pancreatic Cancer

As reported in the Journal of Clinical Oncology by De La Fouchardière et al, the French phase III GEMPAX trial showed no overall survival benefit with second-line gemcitabine/paclitaxel vs gemcitabine alone after FOLFIRINOX (fluorouracil, oxaliplatin, and irinotecan) in patients with metastatic...

prostate cancer

Use of Enzalutamide in Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence

On November 16, 2023, the androgen receptor inhibitor enzalutamide was approved for use in patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.1 Supporting Efficacy Data Approval was based on the EMBARK trial (ClinicalTrials.gov...

supportive care

Antiemetic Strategies for Patients Receiving Highly Emetogenic Chemotherapy

In an Indian single-center phase III trial reported in The Lancet Oncology, Bajpai et al found that low-dose olanzapine was noninferior to standard-dose olanzapine plus triple antiemetic therapy in terms of antiemetic efficacy and reduced daytime somnolence in patients with solid tumors receiving...

kidney cancer

Final Overall Survival Analysis of CLEAR/KEYNOTE-581: Lenvatinib/Pembrolizumab vs Sunitinib in First-Line Treatment of Advanced RCC

As reported in the Journal of Clinical Oncology by Robert J. Motzer, MD, and colleagues, the prespecified final overall analysis of the phase III CLEAR/KEYNOTE-581 trial supported a benefit of lenvatinib/pembrolizumab vs sunitinib in the first-line treatment of advanced renal cell carcinoma. The...

sarcoma

Standard vs Histology-Tailored Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma

In an expanded cohort of a European trial reported in the Journal of Clinical Oncology, Alessandro Gronchi, MD, and colleagues found that histology-tailored neoadjuvant chemotherapy with trabectedin was noninferior in terms of disease-free survival to standard neoadjuvant anthracycline/ifosfamide...

issues in oncology
survivorship

Prevalence of Substance Use Disorders Among U.S. Adult Cancer Survivors

In a study reported in JAMA Oncology, Jones et al found a prevalence of active substance use disorders of 3.8% among U.S. adult survivors of solid tumor cancers, with higher rates among those with head/neck, esophageal/gastric, and cervical cancers as well as melanoma. Study Details The study used...

hepatobiliary cancer

Use of Antiviral Therapy and 10-Year Outcomes in Resected Hepatitis-Related Hepatocellular Carcinoma

In a retrospective cohort study reported in the Journal of Clinical Oncology, Daniel Q. Huang, MBBS, and colleagues found that the use of antiviral therapy was associated with improved overall survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular...

breast cancer

Overall Survival and Long-Term Outcomes in the monarchE Trial

As reported in the Journal of Clinical Oncology by Priya Rastogi, MD, and colleagues, an interim analysis of overall survival in the phase III monarchE trial showed no significant benefit with the addition of 2 years of adjuvant abemaciclib to endocrine therapy in patients with hormone...

colorectal cancer

Addition of Cetuximab Maintenance to First-Line FOLFIRI/Cetuximab in RAS/BRAF Wild-Type Colorectal Cancer

As reported in the Journal of Clinical Oncology by Pinto et al, the Italian phase III ERMES trial showed that the addition of cetuximab maintenance to eight cycles of first-line FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus cetuximab did not achieve noninferiority in terms of...

lymphoma

Follicular Lymphoma: Long-Term Follow-up of Rituximab Dosing Strategies Among Patients With Low Tumor Burden

As reported in the Journal of Clinical Oncology by Brad S. Kahl, MD, and colleagues, long-term follow-up of the phase III Eastern Cooperative Oncology Group RESORT study (E4402) showed that rituximab maintenance did not improve overall survival vs rituximab retreatment in rituximab induction...

gynecologic cancers

Normal Risk Ovarian Screening Study: Long-Term Update

As reported in the Journal of Clinical Oncology by Han et al, the 21-year update of the Normal Risk Ovarian Screening Study (NROSS) has shown that the NROSS screening strategy remains effective for the detection of ovarian cancer and detection at early disease stages. Study Details   The NROSS...

lung cancer

Repotrectinib in ROS1 Fusion–Positive NSCLC

As reported in The New England Journal of Medicine by Alexander Drilon, MD, and colleagues, the phase I/II TRIDENT-1 trial showed the activity of the next-generation ROS1 tyrosine kinase inhibitor repotrectinib in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) with no...

global cancer care
immunotherapy

Use of Lower-Than-Recommended Doses of Immune Checkpoint Inhibitors in Various Tumor Types: Indian Study

In an Indian single-institution study reported in JCO Global Oncology, Patel et al found that use of lower-than-recommended doses of immune checkpoint inhibitors showed activity across various tumor types. As stated by the investigators: “The cost of immune checkpoint inhibitors limits their...

lymphoma

MRD Status and Outcomes With Obinutuzumab- and Rituximab-Based Treatment in Follicular Lymphoma

In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD) status and related outcomes among patients receiving obinutuzumab- and rituximab-based treatment for previously untreated follicular lymphoma. Study...

breast cancer
genomics/genetics

Genetic Identification of Women at Lower Risk of Breast Cancer

In a retrospective analysis reported in JAMA Oncology, Bolze et al identified a group of women at low risk for breast cancer based on genetic analysis. The findings may support altering cancer screening in this low-risk group. As stated by the investigators, “Genetic information is not being used...

pancreatic cancer

Addition of Avasopasem to SBRT in Localized Pancreatic Cancer

Editor’s note: On publication of this news item reporting on a paper by Dr. Cullen Taniguchi and colleagues, The ASCO Post learned of Dr. Taniguchi’s untimely death on November 14, 2023. To read about the remarkable life and career of Dr. Taniguchi, please visit gsbs.uth.edu. In a phase Ib/II trial ...

lymphoma

Rituximab Maintenance in Younger Patients With Mantle Cell Lymphoma: Long-Term Follow-up

In a long-term analysis from the LYMA trial reported in the Journal of Clinical Oncology, Sarkozy et al found that rituximab maintenance following autologous stem cell transplantation (ASCT) continued to be of benefit vs observation in the first-line treatment of younger patients with mantle cell...

gynecologic cancers

Locally Advanced Cervical Cancer: Addition of Camrelizumab to Neoadjuvant Chemotherapy

In the Chinese phase II NACI trial reported in The Lancet Oncology, Li et al found that neoadjuvant chemotherapy plus camrelizumab produced antitumor activity and had a manageable adverse event profile in patients with locally advanced cervical cancer. Study Details   A total of 85 patients were...

immunotherapy
issues in oncology

Immunotherapy Initiation at the End of Life for Patients With Metastatic Cancers

In an analysis reported in JAMA Oncology, Kerekes et al found that initiation of immunotherapy at the end of life has increased over time in U.S. patients with metastatic cancers. Study Details The retrospective cohort study used data from the National Cancer Database on patients with stage IV...

colorectal cancer

Addition of MRI to CT in Patients Scheduled for Colorectal Liver Metastases Local Therapy

In the European CAMINO study reported in The Lancet Oncology, Görgec et al identified the likelihood of change in treatment plans with the addition of contrast-enhanced magnetic resonance imaging (MRI) in patients scheduled for local therapy for colorectal liver metastases on the basis of...

breast cancer

Leisure-Time Physical Activity and Breast Cancer Risk in Premenopausal Women

As reported in the Journal of Clinical Oncology by Timmins et al, a pooled analysis of 19 international cohorts showed that high vs low self-reported leisure-time physical activity was associated with a reduced risk of premenopausal breast cancer.  Study Details The study used individual-level data ...

colorectal cancer

Non–Locally Advanced Rectal Cancer: Impact of Reduced Use of Neoadjuvant Radiotherapy

In a Dutch nationwide cross-sectional cohort study reported in JAMA Oncology, Hazen et al found that a reduced use of neoadjuvant radiotherapy as part of chemoradiotherapy was not associated with poorer outcomes in patients with non–locally advanced rectal cancer. As stated by the investigators,...

leukemia

Long-Term Results With Front-Line Dasatinib/Blinatumomab for Philadelphia Chromosome–Positive ALL

As reported in the Journal of Clinical Oncology by Foà et al, long-term results of the Italian D-ALBA study have shown that a chemotherapy-free induction/consolidation regimen of dasatinib followed by blinatumomab maintained highly favorable outcomes in the front-line treatment of adult patients...

bladder cancer

Muscle-Invasive Bladder Cancer: 5-Year Survival With dd-MVAC

As reported in The Lancet Oncology by Pfister et al, a 5-year analysis of the French phase III VESPER trial showed no improvement in overall survival with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) vs gemcitabine and cisplatin (GC) in the total perioperative...

breast cancer
lung cancer

Addition of SBRT to Standard-of-Care Systemic Therapy in Oligoprogressive Disease

In the phase II CURB trial reported in The Lancet, Chiaojung Jillian Tsai, MD, PhD, and colleagues found that the addition of stereotactic body radiotherapy (SBRT) to standard-of-care systemic therapy was associated with improved progression-free survival in the total study population of patients...

gastroesophageal cancer
gastrointestinal cancer

Perioperative Pembrolizumab Plus Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer

As reported in The Lancet Oncology by Kohei Shitara, MD, and colleagues, interim analyses of the phase III KEYNOTE-585 trial have shown that the addition of perioperative pembrolizumab to chemotherapy improved pathologic complete response, but did not significantly improve event-free survival, in...

Advertisement

Advertisement




Advertisement